0000874015-26-000177
SEC filingRevenue grew 87% to $246.1M from TRYNGOLZA and DAWNZERA product sales, driving 20% narrower operating loss to -$117.4M despite rising commercialization costs, though cash use spiked to -$792.8M on operating activities.
Revenue rose 87% year over year to $246.1 million in Q1 2026 from $131.6 million, primarily driven by TRYNGOLZA and DAWNZERA product sales. This acceleration reflects successful commercialization of these new launches, enabling Ionis to capture growing demand in their respective indications while recognizing R&D revenue from collaborative cost-sharing arrangements, such as with AstraZeneca where Ionis leads Phase 3 development.
Gross profit increased 86.8% to $243.1 million, yielding a near-perfect 98.8% gross margin. This stems from accounting treatment for newly launched products like TRYNGOLZA and DAWNZERA: cost of sales excludes full manufacturing costs until post-launch inventory production and sales, as pre-launch inventory was previously expensed in R&D. Consequently, the revenue surge translated almost directly to gross profit, underscoring the high-margin nature of Ionis' commercialized RNA-targeted therapies.
Operating income loss narrowed 20.0% to -$117.4 million from -$146.9 million, with operating margin at -47.7%. The improvement occurred because revenue growth outpaced expense increases, though SG&A rose as anticipated due to investments in TRYNGOLZA and DAWNZERA commercialization plus preparations for olezarsen in severe hypertriglyceridemia (sHTG) and zilganersen in Alexander disease (AxD). Management notes these investments are deliberate to support independent commercial launches.
Cash from operating activities showed -$792.8 million use versus -$150.8 million prior year, yielding free cash flow of -$814.6 million after $21.8 million capital expenditures (up from $12.6 million). This spike reflects working capital dynamics tied to revenue ramp and operational investments, though management affirms cash, equivalents, and short-term investments suffice for planned operations and obligations, historically financed via R&D collaborations.
Looking ahead, Ionis expects SG&A and operating expenses (excluding equity compensation) to rise with advancing commercialization, but development expenses to stabilize as late-stage studies conclude and resources shift to earlier pipeline programs. This positions the company to balance commercial momentum with R&D efficiency amid key catalysts like potential approvals.